Search
Antihemophilic Factor Human Action Pathway
smpdb.ca/view/SMP0126841Drug actionAntihemophilic factor human, also known as Hemofil, Koate, and Wilate is used as factor VIII replacement therapy to treat hemophilia A. … Administered intravenously the antihemophilic factor human replaces the abnormal coagulation factor VIII, acting as a cofactor to activate coagulation factor IX and X.
Enzymes: Tissue factor, Coagulation factor VIIIAntihemophilic Factor Human Recombinant Action Pathway
smpdb.ca/view/SMP0126774Drug actionAntihemophilic factor, human recombinant is administered intravenously and acts to correct coagulation defects, by activating coagulation factor X and IX. … Antihemophilic factor, human recombinant of the coagulation Factor VIII, also known as Advate, Adynovate, Helixate, Kogenate, Kovaltry, Novoeight, Recombinate, to treat hemophilia A, von Willebrand disease
Enzymes: Tissue factor, Coagulation factor VIIICoagulation Factor VII Human Action Pathway
smpdb.ca/view/SMP0126839Drug actionCoagulation factor VII human is a coagulation factor also known as Balfaxar, Beriplex, Kcentra and Octaplex to treat hemophilia and Glanzmann's thrombasthenia. … It is administered intravenously it acts in combination with tissue factor activating coagulation factor VIIa, which goes on to subsequently activate coagulation factor X and IX leading to blood clotting
Enzymes: Tissue factor, Coagulation factor VIIIVasopressin Regulation of Water Homeostasis
smpdb.ca/view/SMP0000322Signaling(AVP) by stimulating mechanisms that concentrate the urine and maintain water homeostasis in the organism. … The V2 receptor is expressed in the kidney tubule, predominantly in the distal convoluted tubule and collecting ducts, where its primary property is to respond to the pituitary hormone arginine vasopressin
Human Thrombin Action Pathway
smpdb.ca/view/SMP0126872Drug actionHuman thrombin is a platelet-activating factor also known under the brand names Artiss, Evarrest, Evicel, Evithrom, Tachosil, Tisseel and Vistaseal. … It also acts on coagulation factor XIII to activate it and establish cross-linking of fibrin producing a clot. It is used as a topical application to a surgical site to minimize bleeding.
Drugs: CalciumEnzymes: Tissue factor, Coagulation factor VIIIGlutaminolysis and Cancer
smpdb.ca/view/SMP0002298DiseaseThe transportation of glutamine in and out regulates mTOR activation to coordinate cell growth and proliferation. … Once it reaches malic acid, it is transported outside the mitochondria and transformed into pyruvic acid and lactate.
Drugs: Pyridoxal phosphate · Pyruvic acid · Biotin · Aspartic acid · L-Glutamine · Succinic acid +9 moreEnzymes: Hypoxia-inducible factor 1-alpha inhibitorNicotinate and Nicotinamide Metabolism
smpdb.ca/view/SMP0000048MetabolicNicotinate (niacin) and nicotinamide - more commonly known as vitamin B3 - are precursors of the coenzymes nicotinamide-adenine dinucleotide (NAD+) and nicotinamide-adenine dinucleotide phosphate (NADP … The precursors are fed into the NAD+ biosynthetic pathwaythrough adenylation and phosphoribosylation reactions.
Fructose and Mannose Degradation
smpdb.ca/view/SMP0000064MetabolicFructose causes less of an insulin response compared to glucose and thus may be a preferred sugar for diabetics. … Fructose and mannose are monosaccharides that can be found in many foods. Fructose can join with glucose to form sucrose. Mannose can be converted to glucose. Both may be used as food sweeteners.
Androgen and Estrogen Metabolism
smpdb.ca/view/SMP0000068MetabolicThis pathway describes the inactivation and catabolism of male (androgen) and female (estrogen) hormones. … Many steroid hormones are transformed by sulfatases, dehydrogenases and glucuronide transferases to enhance their solubility and to facilitate their elimination.
NAD+ Signalling and Aging
smpdb.ca/view/SMP0084271SignalingAn interesting link has emerged between NAD+ metabolism, SIRT1, SIRT3, and mitochondrial function. … NR and PARP inhibitors increased life span in worms via activation of the mitochondrial unfolded protein response UPRmt by sir2.1.